TWI810550B - 3-氮雜二環烷基衍生物及包含其之醫藥組成物 - Google Patents

3-氮雜二環烷基衍生物及包含其之醫藥組成物 Download PDF

Info

Publication number
TWI810550B
TWI810550B TW110113936A TW110113936A TWI810550B TW I810550 B TWI810550 B TW I810550B TW 110113936 A TW110113936 A TW 110113936A TW 110113936 A TW110113936 A TW 110113936A TW I810550 B TWI810550 B TW I810550B
Authority
TW
Taiwan
Prior art keywords
azabicyclo
acetic acid
methylazetidin
compound
pharmaceutically acceptable
Prior art date
Application number
TW110113936A
Other languages
English (en)
Chinese (zh)
Other versions
TW202202492A (zh
Inventor
李成培
尹碩晙
金昌勳
文喜貞
Original Assignee
南韓商Lg化學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商Lg化學股份有限公司 filed Critical 南韓商Lg化學股份有限公司
Publication of TW202202492A publication Critical patent/TW202202492A/zh
Application granted granted Critical
Publication of TWI810550B publication Critical patent/TWI810550B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110113936A 2020-04-20 2021-04-19 3-氮雜二環烷基衍生物及包含其之醫藥組成物 TWI810550B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200047190 2020-04-20
KR10-2020-0047190 2020-04-20

Publications (2)

Publication Number Publication Date
TW202202492A TW202202492A (zh) 2022-01-16
TWI810550B true TWI810550B (zh) 2023-08-01

Family

ID=78232792

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110113936A TWI810550B (zh) 2020-04-20 2021-04-19 3-氮雜二環烷基衍生物及包含其之醫藥組成物

Country Status (7)

Country Link
US (1) US20230203008A1 (cg-RX-API-DMAC7.html)
EP (1) EP4134366A4 (cg-RX-API-DMAC7.html)
JP (1) JP7618338B2 (cg-RX-API-DMAC7.html)
KR (1) KR102614659B1 (cg-RX-API-DMAC7.html)
CN (1) CN115667244B (cg-RX-API-DMAC7.html)
TW (1) TWI810550B (cg-RX-API-DMAC7.html)
WO (1) WO2021215765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129737A1 (zh) 2019-12-24 2021-07-01 南京明德新药研发有限公司 具有khk抑制作用的化合物
WO2022022476A1 (zh) * 2020-07-28 2022-02-03 山东轩竹医药科技有限公司 己酮糖激酶抑制剂的盐、晶型及其用途
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
JP2024544794A (ja) * 2021-12-24 2024-12-04 エルジー・ケム・リミテッド (s)-2-(2-メチルアゼチジン-1-イル)ピリミジン誘導体およびそれを含む医薬組成物
US20250145619A1 (en) * 2022-02-09 2025-05-08 Youngene Therapeutics Co., Ltd Khk inhibitor, preparation method therefor and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015359624B2 (en) * 2014-12-08 2020-01-02 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
KR102558308B1 (ko) * 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
WO2020156445A1 (zh) * 2019-01-29 2020-08-06 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF

Also Published As

Publication number Publication date
EP4134366A1 (en) 2023-02-15
US20230203008A1 (en) 2023-06-29
EP4134366A4 (en) 2023-10-11
KR102614659B1 (ko) 2023-12-19
JP2023522725A (ja) 2023-05-31
JP7618338B2 (ja) 2025-01-21
TW202202492A (zh) 2022-01-16
WO2021215765A1 (ko) 2021-10-28
KR20210129607A (ko) 2021-10-28
CN115667244A (zh) 2023-01-31
CN115667244B (zh) 2024-04-12

Similar Documents

Publication Publication Date Title
CN111647000B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
TW202202492A (zh) 3-氮雜二環烷基衍生物及包含其之醫藥組成物
TW202509040A (zh) 三環類化合物及其用途
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
WO2024083258A1 (zh) Kras g12d降解剂及其制备方法和应用
WO2023217230A1 (zh) 驱动蛋白kif18a抑制剂及其应用
CN114751903A (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN109912655A (zh) Alk蛋白降解剂及其抗肿瘤应用
WO2022135546A1 (zh) 作为kras-g12c抑制剂的螺环类化合物
CN115209897A (zh) 雷帕霉素类似物及其用途
TW202112783A (zh) 三環類化合物及其用途
CN114075221A (zh) 取代的杂芳基化合物及其组合物和用途
WO2023036156A1 (zh) Dna-pk选择性抑制剂及其制备方法和用途
JP2022502444A (ja) 3−アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物
WO2025218811A1 (zh) pan-KRAS靶向蛋白降解剂及其制备方法和应用
TW201718583A (zh) 新的表皮生長因子受體抑制劑及其應用
WO2024046366A1 (zh) 选择性parp1抑制剂
CN115536660A (zh) 苄氨基取代的杂多环化合物及其组合物、制剂和用途
TWI847445B (zh) 一種噠嗪類化合物、其藥物組合物及應用
CN114787167A (zh) 用于治疗寄生虫病的化合物及组合物
TW202417451A (zh) 抑制irak4活性的化合物及其應用
WO2023098825A1 (zh) Sos1抑制剂、包含其的药物组合物及其用途
TW202333697A (zh) Wnt通路抑制劑化合物
WO2026082051A1 (en) Nitrogen-containing macrocyclic compounds, pharmaceutical composition and use thereof
WO2020147842A1 (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用